Abstract
Apelin is a recently described endogenous peptide and its receptor APJ, is a member of the G protein-coupled receptors family. Apelin and APJ are widely distributed in central and peripheral tissues exert important biological effects on cardiovascular system. Recent studies have suggested that apelin/APJ system involves in decreasing the blood pressure and have a close relationship with hypertension, presumably, pathophysiology of hypertension as well. Such as, apelin/APJ system may be concerned in hyperfunction of the sympathetic nervous system, renin–angiotensin–aldosterone system, endothelial injury, excessive endothelin, sodium retention, vascular remodeling, insulin resistance elicit hypertension, as well as in hypertension-induced organ damaged. Meanwhile, on the ground of the variation of apelin level in hypertension therapeutic process and combining with the recently researches on APJ agonist and antagonist, we could infer that apelin/APJ system would be a promising therapeutic target for hypertension and other cardiovascular disease in the future. However, the role of apelin on these pathogenic conditions was not consistent, consequently, the contradictory role of apelin on these pathogenesis of hypertension would be discussed in this article.
Similar content being viewed by others
References
O’Dowd BF, Heiber M, Chan A, Heng HH, Tsui LC, Kennedy JL, Shi X, Petronis A, George SR, Nguyen T (1993) A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 136(1–2):355–360
Tatemoto K, Hosoya M, Habata Y, Fujii R, Kakegawa T, Zou MX, Kawamata Y, Fukusumi S, Hinuma S, Kitada C, Kurokawa T, Onda H, Fujino M (1998) Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 251(2):471–476
Kawamata Y, Habata Y, Fukusumi S, Hosoya M, Fujii R, Hinuma S, Nishizawa N, Kitada C, Onda H, Nishimura O, Fujino M (2001) Molecular properties of apelin: tissue distribution and receptor binding. Biochim Biophys Acta 1538(2–3):162–171
Hosoya M, Kawamata Y, Fukusumi S, Fujii R, Habata Y, Hinuma S, Kitada C, Honda S, Kurokawa T, Onda H, Nishimura O, Fujino M (2000) Molecular and functional characteristics of APJ. Tissue distribution of mRNA and interaction with the endogenous ligand apelin. J Biol Chem 275(28):21061–21067
Sonmez A, Celebi G, Erdem G, Tapan S, Genc H, Tasci I, Ercin CN, Dogru T, Kilic S, Uckaya G, Yilmaz MI, Erbil MK, Kutlu M (2010) Plasma apelin and ADMA Levels in patients with essential hypertension. Clin Exp Hypertens 32(3):179–183
Pan CS, Qi YF, Tang CS (2005) Apelin and its biological effects. Sheng Li Ke Xue Jin Zhan [Prog Physiol] 36(3):223–226
Ishida J, Hashimoto T, Hashimoto Y, Nishiwaki S, Iguchi T, Harada S, Sugaya T, Matsuzaki H, Yamamoto R, Shiota N, Okunishi H, Kihara M, Umemura S, Sugiyama F, Yagami K, Kasuya Y, Mochizuki N, Fukamizu A (2004) Regulatory roles for APJ, a seven-transmembrane receptor related to angiotensin-type 1 receptor in blood pressure in vivo. J Biol Chem 279(25):26274–26279
De Falco M, De Luca L, Onori N, Cavallotti I, Artigiano F, Esposito V, De Luca B, Laforgia V, Groeger AM, De Luca A (2002) Apelin expression in normal human tissues. Vivo 16(5):333–336
Shin K, Pandey A, Liu XQ, Anini Y, Rainey JK (2013) Preferential apelin-13 production by the proprotein convertase PCSK3 is implicated in obesity. FEBS Open Bio 3:328–333. doi:10.1016/j.fob.2013.08.001
O’Carroll AM, Selby TL, Palkovits M, Lolait SJ (2000) Distribution of mRNA encoding B78/apj, the rat homologue of the human APJ receptor, and its endogenous ligand apelin in brain and peripheral tissues. Biochim Biophys Acta 1492(1):72–80
Kleinz MJ, Davenport AP (2004) Immunocytochemical localization of the endogenous vasoactive peptide apelin to human vascular and endocardial endothelial cells. Regul Pept 118(3):119–125
Yang L, Chen LX (2011) Regulatory function of apelin/APJ system on multiple systems. Int J Pathol Clin Med 31(1):42–48
Zhu P, Huang F, Lin F, Yuan Y, Chen F, Li Q (2013) Plasma apelin levels, blood pressure and cardiovascular risk factors in a coastal Chinese population. Ann Med 45(7):494–498
Papadopoulos DP, Mourouzis I, Faselis C, Perrea D, Makris T, Tsioufis C, Papademetriou V (2013) Masked hypertension and atherogenesis: the impact of apelin and relaxin plasma levels. J Clin Hypertens (Greenwich) 15(5):333–336
Tatemoto K, Takayama K, Zou MX, Kumaki I, Zhang W, Kumano K, Fujimiya M (2001) The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 99(2–3):87–92
Jia YX, Lu ZF, Zhang J, Pan CS, Yang JH, Zhao J, Yu F, Duan XH, Tang CS, Qi YF (2007) Apelin activates l-arginine/nitric oxide synthase/nitric oxide pathway in rat aortas. Peptides 28(10):2023–2029
Sato T, Suzuki T, Watanabe H, Kadowaki A, Fukamizu A, Liu PP, Kimura A, Ito H, Penninger JM, Imai Y, Kuba K (2013) Apelin is a positive regulator of ACE2 in failing hearts. J Clin Investig 123(12):5203–5211
Nagano K, Ishida J, Unno M, Matsukura T, Fukamizu A (2013) Apelin elevates blood pressure in ICR mice with LNAMEinduced endothelial dysfunction. Mol Med Rep 7(5):1371–1375
Han X, Zhang DL, Yin DX, Zhang QD, Liu WH (2013) Apelin-13 deteriorates hypertension in rats after damage of the vascular endothelium by ADMA. Can J Physiol Pharmacol 91(9):708–714. doi:10.1139/cjpp-2013-0046
Liu CH, Li X, Chen F, Pan WN, Feng F, Qin XP, Li LF, Su T, Chen LX (2009) ERK1/2 mediated the vasodilatation of apelin-13 on vascular rings of spontaneously hypertensive rat in vitro. Prog Biochem Biophys 36(12):1578–1588
Modgil A, Guo L, O’Rourke ST, Sun C (2013) Apelin-13 inhibits large-conductance Ca(2+)-activated K(+) channels in cerebral artery smooth muscle cells via a PI3-kinase dependent mechanism. PLoS One 8(12):e83051
Zhang Q, Yao F, Raizada MK, O’Rourke ST, Sun C (2009) Apelin gene transfer into the rostral ventrolateral medulla induces chronic blood pressure elevation in normotensive rats. Circ Res 104(12):1421–1428
Davern PJ, Chowdhury S, Jackson KL, Nguyen-Huu TP, Head GA (2013) GABAA receptor dysfunction contributes to high blood pressure and exaggerated response to stress in Schlager genetically hypertensive mice. J Hypertens 32(2):352–362. doi:10.1097/HJH.0000000000000015
Urban D, Ewen S, Ukena C, Linz D, Bohm M, Mahfoud F (2013) Treating resistant hypertension: role of renal denervation. Integr Blood Press Control 6:119–128
Hendel MD, Collister JP (2006) Renal denervation attenuates long-term hypertensive effects of Angiotensin ii in the rat. Clin Exp Pharmacol Physiol 33:1225–1230. doi:10.1111/j.1440-1681.2006.04514.x
Colombari E, Sato MA, Cravo SL, Bergamaschi CT, Campos RR Jr, Lopes OU (2001) Role of the medulla oblongata in hypertension. Hypertension 38:549–554
Seyedabadi M, Goodchild AK, Pilowsky PM (2002) Site-specific effects of apelin-13 in the rat medulla oblongata on arterial pressure and respiration. Auton Neurosci 101(1–2):32–38
Zhang CR, Xia CM, Jiang MY, Zhu MX, Zhu JM, Du DS, Liu M, Wang J, Zhu DN (2013) Repeated electroacupuncture attenuating of apelin expression and function in the rostral ventrolateral medulla in stress-induced hypertensive rats. Brain Res Bull 97:53–62
Gomes RA, Teodoro L, Lopes IC, Bersanetti PA, Carmona AK, Hial V (2008) Angiotensin-converting enzyme in pericardial fluid: comparative study with serum activity. Arq Bras Cardiol 91(3):156–161, 172–178
Orlov SN, Mongin AA (2007) Salt-sensing mechanisms in blood pressure regulation and hypertension. Am J Physiol Heart Circ Physiol 293(4):H2039–H2053
Carlson SH, Wyss JM (2008) Neurohormonal regulation of the sympathetic nervous system: new insights into central mechanisms of action. Curr Hypertens Rep 10:233–240
Hirooka Y, Kishi T, Sakai K, Takeshita A, Sunagawa K (2011) Imbalance of central nitric oxide and reactive oxygen species in the regulation of sympathetic activity and neural mechanisms of hypertension. Am J Physiol Regul Integr Comp Physiol 300:R818–R826. doi:10.1152/ajpregu.00426.2010
Liao TD, Yang XP, Liu YH, Shesely EG, Cavasin MA, Kuziel WA, Pagano PJ, Carretero OA (2008) Role of inflammation in the development of renal damage and dysfunction in angiotensin II-induced hypertension. Hypertension 52(2):256–263
Hartono SP, Knudsen BE, Zubair AS, Nath KA, Textor SJ, Lerman LO, Grande JP (2013) Redox signaling is an early event in the pathogenesis of renovascular hypertension. Int J Mol Sci 14(9):18640–18656
Wang W, Bodiga S, Das SK, Lo J, Patel V, Oudit GY (2012) Role of ACE2 in diastolic and systolic heart failure. Heart Fail Rev 17(4–5):683–691
Chun HJ, Ali ZA, Kojima Y, Kundu RK, Sheikh AY, Agrawal R, Zheng L, Leeper NJ, Pearl NE, Patterson AJ, Anderson JP, Tsao PS, Lenardo MJ, Ashley EA, Quertermous T (2008) Apelin signaling antagonizes Ang II effects in mouse models of atherosclerosis. J Clin Investig 118(10):3343–3354
Fukushima H, Kobayashi N, Takeshima H, Koguchi W, Ishimitsu T (2010) Effects of olmesartan on apelin/APJ and Akt/endothelial nitric oxide synthase pathway in Dahl rats with end-stage heart failure. J Cardiovasc Pharmacol 55(1):83–88
Zhong JC, Huang DY, Liu GF, Jin HY, Yang YM, Li YF, Song XH, Du K (2005) Effects of all-trans retinoic acid on orphan receptor APJ signaling in spontaneously hypertensive rats. Cardiovasc Res 65(3):743–750
Chaney E, Shaw A (2010) Pathophysiology of fluid retention in heart failure. Contrib Nephrol 164:46–53
Niebylski A, Boccolini A, Bensi N, Binotti S, Hansen C, Yaciuk R, Gauna H (2012) Neuroendocrine changes and natriuresis in response to social stress in rats. Stress Health 28(3):179–185
Jaitovich A, Bertorello AM (2010) Salt, Na+, K+-ATPase and hypertension. Life Sci 86(3–4):73–78
Akcilar R, Turgut S, Caner V, Akcilar A, Ayada C, Elmas L, Ozcan TO (2013) Apelin effects on blood pressure and RAS in DOCA-salt-induced hypertensive rats. Clin Exp Hypertens 35(7):550–557
Azizi M, Iturrioz X, Blanchard A, Peyrard S, De Mota N, Chartrel N, Vaudry H, Corvol P, Llorens-Cortes C (2008) Reciprocal regulation of plasma apelin and vasopressin by osmotic stimuli. J Am Soc Nephrol (JASN) 19(5):1015–1024
Llorens-Cortes C, Kordon C (2008) Jacques Benoit lecture: the neuroendocrine view of the angiotensin and apelin systems. J Neuroendocrinol 20(3):279–289
Taheri S, Murphy K, Cohen M, Sujkovic E, Kennedy A, Dhillo W, Dakin C, Sajedi A, Ghatei M, Bloom S (2002) The effects of centrally administered apelin-13 on food intake, water intake and pituitary hormone release in rats. Biochem Biophys Res Commun 291:1208–1212. doi:10.1006/bbrc.2002.6575
Bech JN, Nielsen EH, Pedersen RS, Svendsen KB, Pedersen EB (2007) Enhanced sodium retention after acute nitric oxide blockade in mildly sodium loaded patients with essential hypertension. Am J Hypertens 20(3):287–295
Johnson FK, Johnson RA, Peyton KJ, Durante W (2005) Arginase inhibition restores arteriolar endothelial function in Dahl rats with salt-induced hypertension. Am J Physiol Regul Integr Comp Physiol 288(4):R1057–R1062
Sasaki Y, Noguchi T, Yamamoto E, Giddings JC, Ikeda K, Yamamoto J, Yamori Y (2004) Effects of voluntary exercise on cerebral thrombosis and endothelial function in spontaneously hypertensive rats (SHRSP/Izm). Clin Exp Pharmacol Physiol 31(Suppl 2):S47–S48
Sainani GS, Maru VG (2004) Role of endothelial cell dysfunction in essential hypertension. J Assoc Physicians India 52:966–969
Chen X, Lin YN, Fang DH, Zhang HQ, Huang WJ (2013) Effect of crucumin on vascular endothelial function in atherosclerotic rabbits. China J Chin Mater Medica 38(19):3343–3347
Li X, Zhang X, Li F, Chen L, Li L, Qin X, Gao J, Su T, Zeng Y, Liao D (2010) 14-3-3 mediates apelin-13-induced enhancement of adhesion of monocytes to human umbilical vein endothelial cells. Acta Biochim Biophys Sin 42(6):403–409
Lu Y, Zhu X, Liang GX, Cui RR, Liu Y, Wu SS, Liang QH, Liu GY, Jiang Y, Liao XB, Xie H, Zhou HD, Wu XP, Yuan LQ, Liao EY (2012) Apelin–APJ induces ICAM-1, VCAM-1 and MCP-1 expression via NF-kappaB/JNK signal pathway in human umbilical vein endothelial cells. Amino Acids 43(5):2125–2136. doi:10.1007/s00726-012-1298-7
Malyszko J, Malyszko JS, Pawlak K, Mysliwiec M (2008) Visfatin and apelin, new adipocytokines, and their relation to endothelial function in patients with chronic renal failure. Adv Med Sci 53(1):32–36
Januszewicz A, Lapinski M, Symonides B, Dabrowska E, Kuch-Wocial A, Trzepla E, Ignatowska-Switalska H, Wocial B, Chodakowska J, Januszewicz W (1994) Elevated endothelin-1 plasma concentration in patients with essential hypertension. J Cardiovasc Risk 1(1):81–85
Gendron G, Gobeil F Jr, Morin J, D’Orleans-Juste P, Regoli D (2004) Contractile responses of aortae from WKY and SHR to vasoconstrictors. Clin Exp Hypertens 26(6):511–523
Yamamoto T, Kimura T, Ota K, Shoji M, Inoue M, Sato K, Ohta M, Yoshinaga K (1991) Central effects of endothelin-1 on vasopressin and atrial natriuretic peptide release and cardiovascular and renal function in conscious rats. J Cardiovasc Pharmacol 17 (Suppl 7):S316–318
Strait KA, Stricklett PK, Kohan DE (2007) Altered collecting duct adenylyl cyclase content in collecting duct endothelin-1 knockout mice. BMC Nephrol 8:8. doi:10.1186/1471-2369-8-817Suppl7:S316-318
Uemasu J, Munemura C, Fujihara M, Kawasaki H (1994) Inhibition of plasma endothelin-1 concentration by captopril in patients with essential hypertension. Clin Nephrol 41(3):150–152
Vanourkova Z, Kramer HJ, Huskova Z, Cervenka L, Vaneckova I (2010) Despite similar reduction of blood pressure and renal ANG II and ET-1 levels aliskiren but not losartan normalizes albuminuria in hypertensive Ren-2 rats. Physiol Res 59(3):339–345
Baumbach GL, Heistad DD (1989) Remodeling of cerebral arterioles in chronic hypertension. Hypertension 13(6 Pt 2):968–972
Kidoya H, Takakura N (2012) Biology of the apelin–APJ axis in vascular formation. J Biochem 152(2):125–131
Li F, Li L, Qin X, Pan W, Feng F, Chen F, Zhu B, Liao D, Tanowitz H, Albanese C, Chen L (2008) Apelin-induced vascular smooth muscle cell proliferation: the regulation of cyclin D1. Front Biosci J Virtual Libr 13:3786–3792
Liu C, Su T, Li F, Li L, Qin X, Pan W, Feng F, Chen F, Liao D, Chen L (2010) PI3K/Akt signaling transduction pathway is involved in rat vascular smooth muscle cell proliferation induced by apelin-13. Acta Biochim Biophys Sin 42(6):396–402
Pan WN, Li F, Mao XH, Qin XP, Deng SX, Feng F, Chen F, Li LF, Liao DF, Chen LX (2011) 14-3-3 protein is involved in ERK1/2 signaling trasduction pathway of rat VSMCs proliferation induced by apelin. Prog Biochem Biophys 38(12):1153–1161. doi:10.3724/SP.J.1206.2011.00334
Li L, Li L, Xie F, Zhang Z, Guo Y, Tang G, Lv D, Lu Q, Chen L, Li J (2013) Jagged-1/Notch3 signaling transduction pathway is involved in apelin-13-induced vascular smooth muscle cells proliferation. Acta Biochim Biophys Sin 45(10):875–881. doi:10.1093/abbs/gmt085
Liu QF, Yu HW, You L, Liu MX, Li KY, Tao GZ (2013) Apelin-13-induced proliferation and migration induced of rat vascular smooth muscle cells is mediated by the upregulation of Egr-1. Biochem Biophys Res Commun 439(2):235–240. doi:10.1016/j.bbrc.2013.08.051
Xun P, Wu Y, He Q, He K (2013) Fasting insulin concentrations and incidence of hypertension, stroke, and coronary heart disease: a meta-analysis of prospective cohort studies. Am J Clin Nutr 98(6):1543–1554. doi:10.3945/ajcn.113.065565
Takatori S, Zamami Y, Hashikawa-Hobara N, Kawasaki H (2013) Insulin resistance-induced hypertension and a role of perivascular CGRPergic nerves. Curr Protein Pept Sci 14(4):275–281
Muniyappa R, Sowers JR (2013) Role of insulin resistance in endothelial dysfunction. Rev Endocr Metab Disord 14(1):5–12. doi:10.1007/s11154-012-9229-1
Togashi N, Maeda T, Yoshida H, Koyama M, Tanaka M, Furuhashi M, Shimamoto K, Miura T (2012) Angiotensin II receptor activation in youth triggers persistent insulin resistance and hypertension—a legacy effect? Hypertens Res 35(3):334–340. doi:10.1038/hr.2011.206
Horita S, Seki G, Yamada H, Suzuki M, Koike K, Fujita T (2011) Insulin resistance, obesity, hypertension, and renal sodium transport. Int J Hypertens 2011:391762
Yue P, Jin H, Aillaud M, Deng AC, Azuma J, Asagami T, Kundu RK, Reaven GM, Quertermous T, Tsao PS (2010) Apelin is necessary for the maintenance of insulin sensitivity. Am J Physiol Endocrinol Metab 298(1):E59–E67. doi:10.1152/ajpendo.00385.2009
Zhu S, Sun F, Li W, Cao Y, Wang C, Wang Y, Liang D, Zhang R, Zhang S, Wang H, Cao F (2011) Apelin stimulates glucose uptake through the PI3K/Akt pathway and improves insulin resistance in 3T3-L1 adipocytes. Mol Cell Biochem 353(1–2):305–313. doi:10.1007/s11010-011-0799-0
Duparc T, Colom A, Cani PD, Massaly N, Rastrelli S, Drougard A, Le Gonidec S, Mouledous L, Frances B, Leclercq I, Llorens-Cortes C, Pospisilik JA, Delzenne NM, Valet P, Castan-Laurell I, Knauf C (2011) Central apelin controls glucose homeostasis via a nitric oxide-dependent pathway in mice. Antioxid Redox Signal 15(6):1477–1496
Wang L, Hou L, Li H, Chen J, Kelly TN, Jaquish CE, Rao DC, Hixson JE, Hu D, Chen CS, Gu C, Chen S, Lu X, Whelton PK, He J, Lu F, Huang J, Liu DP, Gu D (2010) Genetic variants in the renin–angiotensin system and blood pressure reactions to the cold pressor test. J Hypertens 28(12):2422–2428. doi:10.1097/HJH.0b013e32833ea74e
Yang B, Liu X, Li M, Yang Y, Na X, Wang Y (2013) Genetic association of rs1800780 (A→G) polymorphism of the eNOS gene with susceptibility to essential hypertension in a Chinese Han population. Biochem Genet. doi:10.1007/s10528-013-9628-3
Burrell LM, Risvanis J, Dean RG, Patel SK, Velkoska E, Johnston CI (2013) Age-dependent regulation of renal vasopressin V(1A) and V(2) receptors in rats with genetic hypertension: implications for the treatment of hypertension. J Am Soc Hypertens (JASH) 7(1):3–13. doi:10.1016/j.jash.2012.11.004
Li WW, Niu WQ, Zhang Y, Wu S, Gao PJ, Zhu DL (2009) Family-based analysis of apelin and AGTRL1 gene polymorphisms with hypertension in Han Chinese. J Hypertens 27(6):1194–1201
Jin W, Su X, Xu M, Liu Y, Shi J, Lu L, Niu W (2012) Interactive association of five candidate polymorphisms in Apelin/APJ pathway with coronary artery disease among Chinese hypertensive patients. PLoS One 7(12):e51123
Huang J, Chen S, Lu X, Zhao Q, Rao DC, Jaquish CE, Hixson JE, Chen J, Wang L, Cao J, Li J, Li H, He J, Liu DP, Gu D (2012) Polymorphisms of ACE2 are associated with blood pressure response to cold pressor test: the GenSalt study. Am J Hypertens 25(8):937–942
Sedaghat S, Hoorn EJ, van Rooij FJ, Hofman A, Franco OH, Witteman JC, Dehghan A (2013) Serum uric acid and chronic kidney disease: the role of hypertension. PLoS One 8(11):e76827. doi:10.1371/journal.pone.0076827
Seifi B, Kadkhodaee M, Karimian SM, Zahmatkesh M, Xu J, Soleimani M (2010) Evaluation of renal oxidative stress in the development of DOCA-salt induced hypertension and its renal damage. Clin Exp Hypertens 32(2):90–97. doi:10.3109/10641960902993111
Drukteinis JS, Roman MJ, Fabsitz RR, Lee ET, Best LG, Russell M, Devereux RB (2007) Cardiac and systemic hemodynamic characteristics of hypertension and prehypertension in adolescents and young adults: the Strong Heart Study. Circulation 115(2):221–227. doi:10.1161/circulationaha.106.668921
Muller M, van der Graaf Y, Visseren FL, Mali WP, Geerlings MI (2012) Hypertension and longitudinal changes in cerebral blood flow: the SMART-MR study. Ann Neurol 71(6):825–833. doi:10.1002/ana.23554
Sagiroglu T, Torun N, Yagci M, Yalta T, Sagiroglu G, Oguz S (2012) Effects of apelin and leptin on renal functions following renal ischemia/reperfusion: an experimental study. Exp Ther Med 3:908–914. doi:10.3892/etm.2012.499
Ceylan-Isik AF, Kandadi MR, Xu X, Hua Y, Chicco AJ, Ren J, Nair S (2013) Apelin administration ameliorates high fat diet-induced cardiac hypertrophy and contractile dysfunction. J Mol Cell Cardiol 63:4–13. doi:10.1016/j.yjmcc.2013.07.002
Zeng H, He X, Hou X, Li L, Chen JX (2014) Apelin gene therapy increases myocardial vascular density and ameliorates diabetic cardiomyopathy via upregulation of sirtuin 3. Am J Physiol Heart Circ Physiol 306:H585–H597. doi:10.1152/ajpheart.00821.2013
Gu Q, Zhai L, Feng X, Chen J, Miao Z, Ren L, Qian X, Yu J, Li Y, Xu X, Liu CF (2013) Apelin-36, a potent peptide, protects against ischemic brain injury by activating the PI3K/Akt pathway. Neurochem Int 63(6):535–540. doi:10.1016/j.neuint.2013.09.017
Yang L, Su T, Lv D, Xie F, Liu W, Cao J, Sheikh IA, Qin X, Li L, Chen L (2014) ERK1/2 mediates lung adenocarcinoma cell proliferation and autophagy induced by apelin-13. Acta Biochim Biophys Sin. doi:10.1093/abbs/gmt140
Xie F, Li L, Chen L (2013) Autophagy, a new target for disease treatment. Sci China Life Sci 56(9):856–860. doi:10.1007/s11427-013-4530-0
Xie F, Liu W, Chen LX (2012) The progress of autophagy involved in heart disease. Pro Biochem Biophys 39(03):224–233. doi:10.3724/SP.J.1206.2012.00088
Li LF, Li LF, He L, Zhang ZD, Xie F, Guo Y, Xiao JH, Chen LX, Li J (2014) Effects of apelin-13 on rat bone marrow-derived mesenchymal stem cell proliferation through the AKT/GSK3β/cyclin D1 pathway. Int J Pept Res Ther. doi:10.1007/s10989-014-9404-1
Xiao L, Li LF, Chen LX (2013) Progress on the autophagy in vessel function and related diseases. Prog Biochem Biophys 40(01):1171–1185. doi:10.3724/SP.J.1206.2012.00623
Jin G, Yang P, Gong Y, Fan X, Tang J, Lin J (2009) Effects of puerarin on expression of apelin and its receptor of 2K1C renal hypertension rats. China J Chin Mater Med 34(24):3263–3267
Huang ZG, Bai S, Chen L, Wang JT, Ding BP (2013) Effect of puerarin combined with felodipine on mRNA and protein expression of apelin and APJ in renovascular hypertensive rat. China J Chin Mater Med 38(3):381–385
Zhang J, Ren CX, Qi YF, Lou LX, Chen L, Zhang LK, Wang X, Tang C (2006) Exercise training promotes expression of apelin and APJ of cardiovascular tissues in spontaneously hypertensive rats. Life Sci 79(12):1153–1159
Lv D, Li H, Chen L (2013) Apelin and APJ, a novel critical factor and therapeutic target for atherosclerosis. Acta Biochim Biophys Sin 45(7):527–533. doi:10.1093/abbs/gmt040
Xie F, Li LF, Chen LX (2013) Apelin/APJ receptor as myocardial cell baroreceptor induced myocardial hypertrophy formation. Prog Biochem Biophys 40(01):33–36. doi:10.3724/SP.J.1206.2012.00416
Lv D, Lu Q, Cao J, Chen L (2013) Unanticipated role of apelin: regulation of miRNA generation. Acta Biochim Biophys Sin 45(10):896–898. doi:10.1093/abbs/gmt090
Iturrioz X, Alvear-Perez R, De Mota N, Franchet C, Guillier F, Leroux V, Dabire H, Le Jouan M, Chabane H, Gerbier R, Bonnet D, Berdeaux A, Maigret B, Galzi JL, Hibert M, Llorens-Cortes C (2010) Identification and pharmacological properties of E339-3D6, the first nonpeptidic apelin receptor agonist. FASEB J 24(5):1506–1517. doi:10.1096/fj.09-140715
Macaluso NJ, Pitkin SL, Maguire JJ, Davenport AP, Glen RC (2011) Discovery of a competitive apelin receptor (APJ) antagonist. ChemMedChem 6(6):1017–1023. doi:10.1002/cmdc.201100069
Maloney PR, Khan P, Hedrick M, Gosalia P, Milewski M, Li L, Roth GP, Sergienko E, Suyama E, Sugarman E, Nguyen K, Mehta A, Vasile S, Su Y, Stonich D, Nguyen H, Zeng FY, Novo AM, Vicchiarelli M, Diwan J, Chung TD, Smith LH, Pinkerton AB (2012) Discovery of 4-oxo-6-((pyrimidin-2-ylthio)methyl)-4H-pyran-3-yl 4-nitrobenzoate (ML221) as a functional antagonist of the apelin (APJ) receptor. Bioorg Med Chem Lett 22(21):6656–6660. doi:10.1016/j.bmcl.2012.08.105
Acknowledgement
This work was supported by the grants from the National Natural Science Foundation of China (81270420, 30901577), the Hengyang Joint Funds of Hunan Provincial Natural Science Foundation of China (12JJ8013), Hunan Provincial Natural Science Foundation of China (14JJ3102), and the Construct Program of the Key Discipline in Hunan Province. We special appreciate Bingbing Wang (Assistant Professor, Perinatal Biology Laboratory, Division of Maternal-Fetal Medicine, Rutgers University-Robert Wood Johnson Medical School, USA) for the English language improvement.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Wu, D., He, L. & Chen, L. Apelin/APJ system: a promising therapy target for hypertension. Mol Biol Rep 41, 6691–6703 (2014). https://doi.org/10.1007/s11033-014-3552-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11033-014-3552-4